Abstract
Preterm birth (PTB) is a leading cause of neonatal mortality and morbidity worldwide, and surviving infants are at increased risks of lifelong complications. PTB has been firmly linked to inflammation regardless of infection, specific aetiology or timing of birth. Deleterious inflammation is observed in maternal and fetal tissue, and correlates with the severity of perinatal complications. At present, PTB is treated with tocolytics as though it is exclusively a myometrial contractile disorder. These agents do not address underlying inflammatory processes and are thus vastly ineffective at improving neonatal outcomes. Of all inflammatory mediators, IL-1 is central to the pathophysiology of PTB and most adverse neonatal outcomes. We thus present herein a review of the various effects of IL-1 in utero, with a brief overview of its mechanism of action. We then discuss the potential of different IL-1-targeting agents based on pre-clinical testing in relevant models of PTB and neonatal inflammatory injuries.
Keywords: Interleukin-1, preterm labor, preterm birth, inflammation, neonatal injuries, neonatal mortality.
Current Pharmaceutical Design
Title:Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists
Volume: 23 Issue: 40
Author(s): Mathieu Nadeau-Vallee, Dima Obari, Alexandra Beaudry-Richard, Estefania Marin Sierra, Alexandre Beaulac, Noemie Maurice, David M. Olson*Sylvain Chemtob*
Affiliation:
- Departments of Obstetrics and Gynecology, Pediatrics and Physiology, University of Alberta, Edmonton, T6G 2R3,Canada
- Departments of Pediatrics, Ophthalmology and Pharmacology, CHU Sainte-Justine Research Center, Montreal, H3T 1C5,Canada
Keywords: Interleukin-1, preterm labor, preterm birth, inflammation, neonatal injuries, neonatal mortality.
Abstract: Preterm birth (PTB) is a leading cause of neonatal mortality and morbidity worldwide, and surviving infants are at increased risks of lifelong complications. PTB has been firmly linked to inflammation regardless of infection, specific aetiology or timing of birth. Deleterious inflammation is observed in maternal and fetal tissue, and correlates with the severity of perinatal complications. At present, PTB is treated with tocolytics as though it is exclusively a myometrial contractile disorder. These agents do not address underlying inflammatory processes and are thus vastly ineffective at improving neonatal outcomes. Of all inflammatory mediators, IL-1 is central to the pathophysiology of PTB and most adverse neonatal outcomes. We thus present herein a review of the various effects of IL-1 in utero, with a brief overview of its mechanism of action. We then discuss the potential of different IL-1-targeting agents based on pre-clinical testing in relevant models of PTB and neonatal inflammatory injuries.
Export Options
About this article
Cite this article as:
Nadeau-Vallee Mathieu , Obari Dima , Beaudry-Richard Alexandra , Sierra Marin Estefania , Beaulac Alexandre , Maurice Noemie , Olson M. David *, Chemtob Sylvain *, Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists, Current Pharmaceutical Design 2017; 23 (40) . https://dx.doi.org/10.2174/1381612823666170825145114
DOI https://dx.doi.org/10.2174/1381612823666170825145114 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Non-Invasive Diagnostic Tools for Investigating Endothelial Dysfunction
Current Pharmaceutical Design MicroRNAs and Bone Regeneration
Current Genomics Early Life Stress in Depressive Patients: Role of Glucocorticoid and Mineralocorticoid Receptors and of Hypothalamic-Pituitary-Adrenal Axis Activity
Current Pharmaceutical Design Using β-Amino Acids and β-Peptide Templates to Create Bioactive Ligands and Biomaterials
Current Pharmaceutical Design Development and Evaluation of Naproxen Sodium Gel Using Piper cubeba for Enhanced Transdermal Drug Delivery and Therapeutic Facilitation
Recent Patents on Drug Delivery & Formulation AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease
Current Alzheimer Research Statins in Aortic Disease
Current Pharmaceutical Design Editorial (Thematic Issue: Biologics in Autoimmune Diseases)
Current Pharmaceutical Biotechnology Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Interleukin-5, Eosinophilic Diseases and Therapeutic Intervention
Current Drug Targets - Inflammation & Allergy Genomic Strategies in Pharmacology of Asthma and Autoimmunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bronchiolitis Obliterans Following Lung Transplantation and Stem Cell Transplantation in Pediatric Patients
Current Pediatric Reviews Role of Phytochelators in Land Reclamation: Recent Progress and Perspectives
Current Environmental Engineering Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology Editorial (Hot Topic: Emerging Therapeutic Targets in Inflammation and Allergy Drug Discovery from Patent Perspective)
Recent Patents on Inflammation & Allergy Drug Discovery A Simplified Protocol for Routine Chemoselective Syntheses of Piperazines Substituted in the 1-Position by an Electron Withdrawing Group
Current Organic Synthesis Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews Subject Index to Volume 1
Current Drug Delivery